Condition: Alpha 1-Antitrypsin Deficiency · Sponsor: Beam Therapeutics Inc.
This is a Phase 1/2, multicenter, open-label, dose-exploration (Phase 1) and dose-expansion (Phase 2) study to evaluate the safety, tolerability, PK/PD, and efficacy of BEAM-302 in adult patients with AATD-associated lung disease and/or liver disease and to determine the optimal biological dose (OBD).
This description comes directly from the study's public registry record.
Medical Information · 857-327-8641 · clinicalinfo@beamtx.com
Always discuss trial participation with your own doctor first.
| Clinical Study Center | Birmingham, Alabama, United States | Recruiting |
| Clinical Study Center | Boston, Massachusetts, United States | Recruiting |
| Clinical Study Center | Charleston, South Carolina, United States | Recruiting |
| Clinical Study Center | Adelaide, Australia | Recruiting |
| Clinical Study Center | Fitzroy, Australia | Recruiting |
| Clinical Study Center | Dublin, Ireland | Recruiting |
| Clinical Study Center | Leiden, Netherlands | Recruiting |
| Clinical Study Center | Auckland, New Zealand | Recruiting |
| Clinical Study Center | Hamilton, New Zealand | Recruiting |
| Clinical Study Center | London, United Kingdom | Recruiting |
| Clinical Study Center | Southampton, United Kingdom | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06389877